Afuresertib (GSK2110183)

Name: Afuresertib (GSK2110183)
Brand: Selleck Chemicals
SKU: S7521
Rating: 5 (17 reviews)

For research use only.

Catalog No.S7521

17 publications

Afuresertib (GSK2110183) Chemical Structure

CAS No. 1047644-62-1

Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with K_i of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

Selleck's Afuresertib (GSK2110183) has been cited by 17 publications

Nat Chem Biol, 2017, 13(3):333-338

PubMed: 28114274 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):121

PubMed: 34035227 ( click the link to review the publication )

Cell Chem Biol, 2021, S2451-9456(21)00400-1

PubMed: 34525344 ( click the link to review the publication )

Oncol Rep, 2021, 45(4):1

PubMed: 33649826 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4629

PubMed: 32934208 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 8

PubMed: 32382996 ( click the link to review the publication )

Cancer Sci, 2020, 111(5):1663-1675

PubMed: 32176823 ( click the link to review the publication )

Hum Cell, 2020, 33(4):1197-1203

PubMed: 32851605 ( click the link to review the publication )

Blood Adv, 2020,

PubMed: 32898245 ( click the link to review the publication )

Nat Commun, 2019, 10(1):95

PubMed: 30626865 ( click the link to review the publication )

Cancers (Basel), 2019, 22;11(7):1029

PubMed: 31336622 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 381:114729

PubMed: 31445927 ( click the link to review the publication )

J Clin Invest, 2018, 128(10):4604-4621

PubMed: 30106752 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6408-6420

PubMed: 30126942 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):911

PubMed: 30185800 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9450-9456

PubMed: 29928335 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

1 Customer Review

Analysis of the mechanism of action of the enhanced anti‑tumor effect of the combination therapy of suboptimal doses of pomalidomide plus dexamethasone and afuresertib in MM cells. (A‑C) The altered expression of protein substrates was analyzed in two MM cell lines that were treated with suboptimal doses of PD, or AFU, or the PD and AFU combination. The XG‑7 and U266 cell lines were subjected to the indicated treatments for 48 and 72 h, respectively. (A) Caspases, (B) substrates related mainly to the working mechanism of IMiDs, (C) substrates mainly related to the working mechanism of afuresertib, and (D) two primary MM cell cultures, were subjected to the analysis in the same manner as the two MM cell lines. In the expression panel of p‑FoxO3a/FoxO1, the upper band represents p‑FoxO3a and the lower band represents p‑FOXO1. PD, pomalidomide plus dexamethasone; AFU, Afuresertib; MM, multiple myeloma; IMiDs, immunomodulatory drugs.

ONCOLOGY LETTERS, 2018, https://doi.org/10.3892/ol.2018.8501. Afuresertib (GSK2110183) purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description

Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with K_i of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

Targets

Akt1 ^[1] (Cell-free assay)	Akt2 ^[1] (Cell-free assay)	Akt3 ^[1] (Cell-free assay)
0.08 nM(Ki)	2 nM(Ki)	2.6 nM(Ki)

In vitro

Afuresertib inhibits the kinase activity of the E17K AKT1 mutant protein with EC50 of 0.2 nM. Afuresertib shows a concentration-dependent effect on multiple AKT substrate phosphorylation levels, including GSK3b, PRAS40, FOXO and Caspase 9. Overall 65% of the hematological cell lines are sensitive to afuresertib (EC50 < 1 μM). Among tested solid tumor cell lines, 21% have EC50 < 1 μM in response to afuresertib.^[1]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
Sf9	NYXBb5JCTnWwY4Tpc44h[XO\|YYm=	M3HRW\|QxKG2rboO=	M1LZbWlvcGmkaYTpc44hd2ZiZoXscEBt\W6pdHigbJVu[W5iQVvUNUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiC\|dXLzeJJifGVicHjvd5Bpd3K7bHH0bY9vKHW\|aX7nJIJqd3Srbj3hbJguSVKNUlXSRXlUTkeKSFGtZY1q\GVic4Xid5Rz[XSnIHHu[EBc\2GvbXGtN\|NRZUGWUDDpcoN2[mG2ZXSg[o9zKDRyIH3pcpMh[nlidH;wJINwfW62IH3pZ5JweGyjdHWgd4NqdnSrbHzheIlwdiClb4XueIlv\yCvZYToc4QtKEmFNUCgQUAxNjByMTFOwG0v	NXfWXHk2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
Sf9	NIDLO4NHfW6ldHnvckBie3OjeR?=	M4DJbFQxKG2rboO=	NYrocY81UW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBpfW2jbjDBT3Q{KGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIIP1ZpN1emG2ZTDwbI9{eGixconsZZRqd25idYPpcoch[mmxdHnuMYFpgC2DUlvSSXJCYVOIR1jIRU1idWmmZTDzeYJ{fHKjdHWgZY5lKFupYX3tZU0{O1CfQWTQJIlv[3WkYYTl[EBnd3JiNECgcYlveyCkeTD0c5Ah[2:3boSgcYlkem:ybHH0[UB{[2mwdHnscIF1cW:wIHPveY51cW6pIH3leIhw\CxiSVO1NEA:KDBwMECxOVg2KM7:TT6=	NHrRV3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
COLO205	M1L1S2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MV63NkBpenN?	NUPOXnFFT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OT{KwOUBk\WyuczDheEAyQjFyIH3vcIFzKHKjdHnvJI9nKGOxbYDveY5lKGmwIIDy[ZNmdmOnIH;mJG4ugzNvW{OtZ5lkdG:ycn;wfYwuPS1qMj3mcJVwem9vND3pc4RwNXCqZX75cIFucW6xKT22MFgu\GmvZYTofYwuKDJuNDy3MZRzcW:6bz2zMFQtPix5LYTleJJicHmmcn:tNmgueHm{aXTvX\|QtOy2mXYD5dolucWSrbj2xMZltZXCqZX75cJ1i[2W2YX3p[IUhcW6ldXLheIVlKG[xcjC3NkBpenNiLDDJR\|UxKD1iMD6wNFkh\|ryPLh?=	M{DYR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
Sf9	NHq5ZY1HfW6ldHnvckBie3OjeR?=	NFnQXpc1OCCvaX7z	MYXJcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIHj1cYFvKEGNVEKg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4he3Wkc4TyZZRmKHCqb4PwbI9zgWyjdHnvckB2e2mwZzDibY91cW5vYXj4MWFTU1KHUlHZV2ZIUEiDLXHtbYRmKHO3YoP0doF1\SCjbnSgX4didW2jLUOzVH1CXFBiaX7jeYJifGWmIH\vdkA1OCCvaX7zJIJ6KHSxcDDjc5VvfCCvaXPyc5Bt[XSnIIPjbY51cWyuYYTpc44h[2:3boTpcochdWW2aH;kMEBKSzVyIE2gNE4xOSEQvF2u	M1G2UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
MV522	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MnTpO\|IhcHK\|	M{C4bWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1XPTJ{IHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3MDC9JFAvODF{IN88UU4>	MkXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
HT-29	MnS1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NEXRRlU4OiCqcoO=	M2nofmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhVNTJ7IHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3MDC9JFAvODF3IN88UU4>	Mn;pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
NCI-H727	NGXxOVJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MUm3NkBpenN?	NI\QTIVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEeyO{Bk\WyuczDheEAyQjFyIH3vcIFzKHKjdHnvJI9nKGOxbYDveY5lKGmwIIDy[ZNmdmOnIH;mJG4ugzNvW{OtZ5lkdG:ycn;wfYwuPS1qMj3mcJVwem9vND3pc4RwNXCqZX75cIFucW6xKT22MFgu\GmvZYTofYwuKDJuNDy3MZRzcW:6bz2zMFQtPix5LYTleJJicHmmcn:tNmgueHm{aXTvX\|QtOy2mXYD5dolucWSrbj2xMZltZXCqZX75cJ1i[2W2YX3p[IUhcW6ldXLheIVlKG[xcjC3NkBpenNuIFnDOVAhRSByLkCxPUDPxE1w	NHTqdGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
SW1417	MmXQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NYfncmtnPzJiaILz	MlfGS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV3cyPDF5IHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3MDC9JFAvODNizszNMi=>	NIK4W\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
Calu6	NWXtbXN{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MXq3NkBpenN?	NVXDdZd6T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hS2GudU[gZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt\|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJJ{NCCLQ{WwJF0hOC5yM{Gg{txONg>?	M1XhSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
LS1034	NH3EWI5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1W2NFczKGi{cx?=	MnT2S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUHMyODN2IHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3MDC9JFAvODRizszNMi=>	NFO4eYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
SW1463	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M3vIelczKGi{cx?=	M32ze2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNYOTR4MzDj[YxteyCjdDCxPlExKG2xbHHyJJJifGmxIH;mJINwdXCxdX7kJIlvKHC{ZYPlcoNmKG:oIF6tf\|MuYzNvY4njcI9xem:yeXytOU0pOi2obIXvdo8uPC2rb3TvMZBp\W67bHHtbY5wMS14LEit[Ilu\XSqeXytJFItPCx5LYTybY95dy1\|LESsOkw4NXSndILhbJllem9vMlitdJlzcWSxW{SsN{1lZXC7cnntbYRqdi1zLYnsYZBp\W67bI3hZ4V1[W2rZHWgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUCgQUAxNjB2MTFOwG0v	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
RKO	NUPSPWNbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MkLpO\|IhcHK\|	NGLtPJhIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBTU09iY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW\|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4xPTRizszNMi=>	M3vYZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
NCI-H508	MljrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NH3jU5g4OiCqcoO=	NWn2dJNuT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NFgh[2WubIOgZZQhOTpzMDDtc4xieiC{YYTpc{Bw\iClb33wc5Vv\CCrbjDwdoV{\W6lZTDv[kBPNXt\|LWuzMYN6[2yxcILvdJltNTVvKEKt[ox2d3KxLUStbY9ldy2yaHXufYxidWmwbzmtOkw5NWSrbXX0bJltNSB{LESsO{11emmxeH:tN{w1NDZuNz30[ZRz[Wi7ZILvMVJJNXC7cnnkc3s1NDNvZG3wfZJqdWmmaX6tNU16dF2yaHXufYx:[WOndHHtbYRmKGmwY4XiZZRm\CCob4KgO\|IhcHK\|LDDJR\|UxKD1iMD6wPEDPxE1w	M3ftVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
NCI-H1155	MojFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MX63NkBpenN?	MmTsS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUhzMUW1JINmdGy\|IHH0JFE7OTBibX;sZZIhemG2aX:gc4Yh[2:vcH;1coQhcW5icILld4Vv[2Vib3[gUk18Oy2dMz3jfYNtd3C{b4D5cE02NSh{LX\seY9zdy12LXnv[I8ueGinbonsZY1qdm9rLU[sPE1lcW2ndHj5cE0hOix2LEeteJJqd3ixLUOsOEw3NDdvdHX0doFpgWS{bz2yTE1xgXKrZH;bOEw{NWSfcInybY1q\GmwLUGtfYxeeGinbonsgYFk\XSjbXnk[UBqdmO3YnH0[YQh\m:{IEeyJIhzNCCLQ{WwJF0hOC5zMEGg{txONg>?	Mn7JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
A427	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NXvEN\|lOPzJiaILz	NUDyWIlOT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxteyCjdDCxPlExKG2xbHHyJJJifGmxIH;mJINwdXCxdX7kJIlvKHC{ZYPlcoNmKG:oIF6tf\|MuYzNvY4njcI9xem:yeXytOU0pOi2obIXvdo8uPC2rb3TvMZBp\W67bHHtbY5wMS14LEit[Ilu\XSqeXytJFItPCx5LYTybY95dy1\|LESsOkw4NXSndILhbJllem9vMlitdJlzcWSxW{SsN{1lZXC7cnntbYRqdi1zLYnsYZBp\W67bI3hZ4V1[W2rZHWgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUCgQUAxNjFyMzFOwG0v	NXHVTWc2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
KM12	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NHvYT4Y4OiCqcoO=	MUDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDLUVEzKGOnbHzzJIF1KDF8MUCgcY9t[XJicnH0bY8hd2ZiY3;tdI92dmRiaX6gdJJme2WwY3Wgc4YhVi29Mz3bN{1kgWOub4Dyc5B6dC13LTiyMYZtfW:{bz20MYlw\G9vcHjlcplt[W2rbn:pMVYtQC2maX3leIh6dC1iMjy0MFcufHKrb4jvMVMtPCx4LEeteIV1emGqeXTyc{0zUC2yeYLp[I9cPCx\|LXTddJlzcW2rZHnuMVEugWyfcHjlcplthWGlZYThcYll\SCrbnP1ZoF1\WRiZn;yJFczKGi{czygTWM2OCB;IECuNVA1KM7:TT6=	Mk\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
HCT8	NF;1b4VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NHnzXFQ4OiCqcoO=	MmHxS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVQCClZXzsd{BifCBzOkGwJI1wdGG{IILheIlwKG:oIHPvcZBwfW6mIHnuJJBz\XOnbnPlJI9nKE5ve{OtX\|Mu[3mlbH;wdo9xgWxvNT2oNk1ndHWxcn:tOE1qd2SxLYDo[Y56dGGvaX7vLU03NDhvZHnt[ZRpgWxvIEKsOEw4NXS{aX;4c{0{NDRuNjy3MZRmfHKjaInkdo8uOkhvcInybYRwYzRuMz3kYZB6emmvaXTpck0yNXmuXYDo[Y56dH2jY3X0ZY1q\GViaX7jeYJifGWmIH\vdkA4OiCqcoOsJGlEPTBiPTCwMlE1OyEQvF2u	M3O5XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
MDA-MB-175-VII	NGK5bHdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1GwOlczKGi{cx?=	MVrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNSGEuVUJvMUe1MXZKUSClZXzsd{BifCBzOkGwJI1wdGG{IILheIlwKG:oIHPvcZBwfW6mIHnuJJBz\XOnbnPlJI9nKE5ve{OtX\|Mu[3mlbH;wdo9xgWxvNT2oNk1ndHWxcn:tOE1qd2SxLYDo[Y56dGGvaX7vLU03NDhvZHnt[ZRpgWxvIEKsOEw4NXS{aX;4c{0{NDRuNjy3MZRmfHKjaInkdo8uOkhvcInybYRwYzRuMz3kYZB6emmvaXTpck0yNXmuXYDo[Y56dH2jY3X0ZY1q\GViaX7jeYJifGWmIH\vdkA4OiCqcoOsJGlEPTBiPTCwMlE2PSEQvF2u	NXy2TZJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
A549	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MWO3NkBpenN?	MXzHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDBOVQ6KGOnbHzzJIF1KDF8MUCgcY9t[XJicnH0bY8hd2ZiY3;tdI92dmRiaX6gdJJme2WwY3Wgc4YhVi29Mz3bN{1kgWOub4Dyc5B6dC13LTiyMYZtfW:{bz20MYlw\G9vcHjlcplt[W2rbn:pMVYtQC2maX3leIh6dC1iMjy0MFcufHKrb4jvMVMtPCx4LEeteIV1emGqeXTyc{0zUC2yeYLp[I9cPCx\|LXTddJlzcW2rZHnuMVEugWyfcHjlcplthWGlZYThcYll\SCrbnP1ZoF1\WRiZn;yJFczKGi{czygTWM2OCB;IECuNVY1KM7:TT6=	Ml3BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
NCI-H23	NHzue3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MXK3NkBpenN?	MWrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDJ\|IHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{AtKEmFNUCgQUAxNjF7OTFOwG0v	NWDPbWN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
SW837	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MmP5O\|IhcHK\|	NV3DcmNPT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW1d6M{egZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt\|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJJ{NCCLQ{WwJF0hOC5{NEig{txONg>?	M2HLN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
SW480	NUfuPG5MT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXjUbmZ1PzJiaILz	MoXpS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV3c1QDBiY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW\|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4zPTlizszNMi=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
NCI-H1355	M3r4NGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3rEflczKGi{cx?=	MXrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDF\|NUWgZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt\|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJItKEmFNUCgQUAxNjJ4ODFOwG0v	M3vQdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
EFM19	NXzBN\|czT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MXu3NkBpenN?	NULOTIxLT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTU[PMUmgZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt\|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJJ{NCCLQ{WwJF0hOC5\|IN88UU4>	NXfWblV{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
T84	M4Gx[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M4HDPFczKGi{cx?=	MWLHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDUPFQh[2WubIOgZZQhOTpzMDDtc4xieiC{YYTpc{Bw\iClb33wc5Vv\CCrbjDwdoV{\W6lZTDv[kBPNXt\|LWuzMYN6[2yxcILvdJltNTVvKEKt[ox2d3KxLUStbY9ldy2yaHXufYxidWmwbzmtOkw5NWSrbXX0bJltNSB{LESsO{11emmxeH:tN{w1NDZuNz30[ZRz[Wi7ZILvMVJJNXC7cnnkc3s1NDNvZG3wfZJqdWmmaX6tNU16dF2yaHXufYx:[WOndHHtbYRmKGmwY4XiZZRm\CCob4KgO\|IhcHK\|LDDJR\|UxKD1iMD6zNFQh\|ryPLh?=	NGjINGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
COR-L23	NXvOd29PT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MUm3NkBpenN?	M{HEfWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMkOgZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt\|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KCxiSVO1NEA:KDBwM{[4JO69VS5?	MmDoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
NCI-H1792	MlP3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NIrNdo04OiCqcoO=	M3G3XGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe5NkBk\WyuczDheEAyQjFyIH3vcIFzKHKjdHnvJI9nKGOxbYDveY5lKGmwIIDy[ZNmdmOnIH;mJG4ugzNvW{OtZ5lkdG:ycn;wfYwuPS1qMj3mcJVwem9vND3pc4RwNXCqZX75cIFucW6xKT22MFgu\GmvZYTofYwuKDJuNDy3MZRzcW:6bz2zMFQtPix5LYTleJJicHmmcn:tNmgueHm{aXTvX\|QtOy2mXYD5dolucWSrbj2xMZltZXCqZX75cJ1i[2W2YX3p[IUhcW6ldXLheIVlKG[xcjC3NkBpeixiSVO1NEA:KDBwM{e0JO69VS5?	MlrSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
SW1573	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MknqO\|IhcHK\|	MXjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTW\|E2PzNiY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW\|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4{QDJizszNMi=>	NITMdIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
Calu3	M4jjdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MmX4O\|IhcHK\|	M4nHXWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGNidHV\|IHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3MDC9JFAvOzl{IN88UU4>	M4m0[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
HCC827	Mmi5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M4fwflczKGi{cx?=	MWDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR2M5OjdiY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW\|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE41ODFizszNMi=>	M4DjbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
EFM19	NGHsbHBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NYm1Rm9nPzJiaILz	MkHHS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSWZOOTliY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgR4VtdC22aYTldk1IdG9icnXh[4VvfCCkYYPl[EBie3OjeTygTWM2OCB;IECuOFMh\|ryPLh?=	M1PHfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
HOP62	NHPaN4tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NX6wco9rPzJiaILz	NGX0SnFIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJV1B4MjDj[YxteyCjdDCxPlExKG2xbHHyJJJifGmxIH;mJINwdXCxdX7kJIlvKHC{ZYPlcoNmKG:oIF6tf\|MuYzNvY4njcI9xem:yeXytOU0pOi2obIXvdo8uPC2rb3TvMZBp\W67bHHtbY5wMS14LEit[Ilu\XSqeXytJFItPCx5LYTybY95dy1\|LESsOkw4NXSndILhbJllem9vMlitdJlzcWSxW{SsN{1lZXC7cnntbYRqdi1zLYnsYZBp\W67bI3hZ4V1[W2rZHWgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUCgQUAxNjR7ODFOwG0v	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
NCI-H508	MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M2q3OVczKGi{cx?=	NILw[GFIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEWwPEBk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCFZXzsMZRqfGW{LVfsc{Bz\WGpZX70JIJie2WmIHHzd4F6NCCLQ{WwJF0hOC53MkKg{txONg>?	MkXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
SW900	M37hZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M{nORVczKGi{cx?=	NV\wNFZ[T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7MECgZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt\|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJJ{NCCLQ{WwJF0hOC55MUmg{txONg>?	MoHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
MDA-MB-175-VII	MlTtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NVHaZZYyPzJiaILz	NIe5[m9Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNVc2NV[LSTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBE\WyuLYTpeIVzNUeubzDy[YFo\W62IHLhd4VlKGG\|c3H5MEBKSzVyIE2gNE44QTRizszNMi=>	M{jaNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
NCI-H1155	M1u3bmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NYj5UFJiPzJiaILz	Mmr3S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUhzMUW1JINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KEOnbHyteIl1\XJvR3zvJJJm[WenboSgZoF{\WRiYYPzZZktKEmFNUCgQUAxNjh4NTFOwG0v	NXK0cWUzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
DLD1	NFSyOYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NVrnbJhbPzJiaILz	NGPjVHdIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBFVERzIHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3MDC9JFAvQTN{IN88UU4>	NY\mTlVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
HT-29	M1nLVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NHrKNo84OiCqcoO=	M1f6Xmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhVNTJ7IHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO\|YYmsJGlEPTBiPTCxMlM5OyEQvF2u	Moe4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
HCT8	MliwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NFzDfWQ4OiCqcoO=	NVfx[VFjT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWODDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBE\WyuLYTpeIVzNUeubzDy[YFo\W62IHLhd4VlKGG\|c3H5MEBKSzVyIE2gNU42PDFizszNMi=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
RKO	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M4qxWVczKGi{cx?=	NUH0boM2T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWkuRIHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO\|YYmsJGlEPTBiPTCxMlgxPiEQvF2u	NHPMbZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
Calu6	NWjCZ2M5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NH7MR2k4OiCqcoO=	NHK3V3RIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBE[Wy3NjDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBE\WyuLYTpeIVzNUeubzDy[YFo\W62IHLhd4VlKGG\|c3H5MEBKSzVyIE2gNk4yPTRizszNMi=>	NXfTS2N4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
KM12	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MoLxO\|IhcHK\|	M3jp[Wdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGtOOTJiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgR4VtdC22aYTldk1IdG9icnXh[4VvfCCkYYPl[EBie3OjeTygTWM2OCB;IEKuNlQ4KM7:TT6=	NU\oU21nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
COLO205	NEG0RXlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M1HaWlczKGi{cx?=	MYjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDDU2xQOjB3IHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO\|YYmsJGlEPTBiPTCyMlU3PyEQvF2u	M1H0UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
MV522	M1iyd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1L1WVczKGi{cx?=	NGGyVnRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOXjV{MjDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBE\WyuLYTpeIVzNUeubzDy[YFo\W62IHLhd4VlKGG\|c3H5MEBKSzVyIE2gN{4xPDRizszNMi=>	NIfrT3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
LS1034	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M3vEWlczKGi{cx?=	M2XsNGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGxUOTB\|NDDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBE\WyuLYTpeIVzNUeubzDy[YFo\W62IHLhd4VlKGG\|c3H5MEBKSzVyIE2gOE4{OzlizszNMi=>	NUfyfJlKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
NCI-H727	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NXP0VpVrPzJiaILz	M2rON2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{K3JINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KEOnbHyteIl1\XJvR3zvJJJm[WenboSgZoF{\WRiYYPzZZktKEmFNUCgQUA1Njd7OTFOwG0v	NHnn[4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
COR-L23	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1LSfFczKGi{cx?=	M33xOGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMkOgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhS2WubD30bZRmei2JbH:gdoVi\2WwdDDiZZNm\CCjc4PhfUwhUUN3MDC9JFUvOzd\|IN88UU4>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
A549	M3:xdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MlLTO\|IhcHK\|	MWfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDBOVQ6KGOnbHzzJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IFPlcIwufGm2ZYKtS4xwKHKnYXflcpQh[mG\|ZXSgZZN{[XluIFnDOVAhRSB3Lkm5N{DPxE1w	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
NCI-H1355	M2KzR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1rpUVczKGi{cx?=	NETZNYVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGzOVUh[2WubIOgbY5kfWKjdHXkJIZweiB5MjDodpMh[nliQ3XscE11cXSncj3HcI8hemWjZ3XueEBj[XOnZDDhd5NigSxiSVO1NEA:KDZwNki1JO69VS5?	MnXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
NCI-H23	MkGxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MXi3NkBpenN?	NIfqXGtIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKzJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KEOnbHyteIl1\XJvR3zvJJJm[WenboSgZoF{\WRiYYPzZZktKEmFNUCgQUA4NjF{NDFOwG0v	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
NCI-H1792	MnfXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M1XI[VczKGi{cx?=	NFXVZ2lIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3PVIh[2WubIOgbY5kfWKjdHXkJIZweiB5MjDodpMh[nliQ3XscE11cXSncj3HcI8hemWjZ3XueEBj[XOnZDDhd5NigSxiSVO1NEA:KDdwM{C3JO69VS5?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
SW1463	NVe0dY9ST3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NIfiWng4OiCqcoO=	NELJcW1Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUXzF2NkOgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhS2WubD30bZRmei2JbH:gdoVi\2WwdDDiZZNm\CCjc4PhfUwhUUN3MDC9JFkvPzJ3IN88UU4>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-GSK3 / GSK3 / p-PRAS40 / PRAS40 / p-FOXO / p-Casp9 / p-AKT / AKT / p-MEK / p-ERK / Erk ; PubMed: 24978597 PLoS One BT474 (left) and LNCaP (right) cell lines were treated with DMSO or GSK2110183 for 1 h. Western analysis was performed to assay levels of phosphorylated and total GSK-3, PRAS40, AKT and ERK, phosphorylated Foxo, Caspase 9, and MEK. Tubulin was used as a loading control. ATG3 / ATG12 / LC3B ; PubMed: 30867818 Theranostics Alterations in autophagy-related proteins induced by AKT inhibition.	24978597 30867818

In vivo

Mice bearing BT474 breast tumor xenografts are dosed with afuresertib (p.o.) at 10, 30 or 100 mg/kg daily which results in 8, 37 and 61% TGI, respectively. Mice bearing SKOV3 ovarian tumor xenografts are treated with 10, 30 and 100 mg/kg afuresertib which results in 23, 37 and 97% TGI, respectively.^[1]

Protocol

Kinase Assay:^[1]	- Collapse Potency (Ki) of afuresertib: The true potency (Ki) of the inhibitor is initially determined at low enzyme concentrations (0.1 nM AKT1, 0.7 nM AKT2, and 0.2 nM AKT3) using a filter binding assay and then confirmed with progress curve analysis. In the filter binding assay, a pre-mix of enzyme plus inhibitor is incubated for 1 h and then added to a GSKα peptide (Ac-KKGGRARTSS-FAEPG-amide) and [γ³³P] ATP. Reactions are terminated after 2 h and the radio labeled AKT peptide product is captured in a phospho-cellulose filter plate. Progress curve analysis utilizes continuous real-time fluorescence detection of product formation using the Sox-AKT-tide substrate (Ac-ARKRERAYSF-d-Pro-Sox-Gly-NH2).
Cell Research:^[1]	- Collapse Cell lines: Hematological cell lines and solid tumor cell lines Concentrations: 30 μM Incubation Time: 72 h Method: A 3-day proliferation assay using CellTiter-Glo is performed to measure the growth inhibition by the compounds at 0-30 μM. Cell growth is determined relative to untreated (DMSO) controls. EC50’s are calculated from inhibition curves using a 4- or 6-parameter fitting algorithm in the Assay Client application. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female athymic nude and SCID mice bearing SKOV3 or BT474 tumors Dosages: 100 mg/kg Administration: p.o. (Only for Reference)

References

[1] Dumble M, et al. PLoS One, 2014, 9(6):e100880.

Solubility (25°C)

In vitro	DMSO	85 mg/mL (198.91 mM)
	Ethanol	85 mg/mL (198.91 mM)
	Water	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Afuresertib (GSK2110183) SDF

Molecular Weight	427.32
Formula	C₁₈H₁₇Cl₂FN₄OS
CAS No.	1047644-62-1
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)NC(CC3=CC(=CC=C3)F)CN)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04374630	Recruiting	Drug: Paclitaxel\|Drug: Afuresertib	Platinum-resistant Ovarian Cancer	Laekna Limited	June 9 2020	Phase 2
NCT04060394	Recruiting	Drug: Phase I and Phase II: LAE001/prednisone + afuresertib	Metastatic Castration-resistant Prostate Cancer	Laekna Limited	September 13 2019	Phase 1\|Phase 2
NCT02235740	Terminated	Drug: Afuresertib\|Drug: Carfilzomib	Cancer	Novartis\|Amgen	November 2014	Phase 1
NCT02240212	Completed	Drug: Afuresertib\|Drug: Paclitaxel	Cancer	Novartis Pharmaceuticals\|Novartis	October 2014	Phase 1
NCT02177682	Terminated	Drug: Afuresertib	Neoplasms Haematologic	Novartis Pharmaceuticals\|Novartis	August 13 2014	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Akt Signaling Pathway Map

Related Akt Products

AT13148 ^New

AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.
SC79 ^New

SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.
TIC10 (ONC201) ^New

TIC10 (ONC201) inactivates Akt and ERK to induce TNF-related apoptosis-inducing ligand (TRAIL) through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
Capivasertib (AZD5363)

Capivasertib (AZD5363) potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.
Ipatasertib (GDC-0068)

Ipatasertib (GDC-0068, RG7440) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.
GSK690693

GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. GSK690693 also potently inhibits AMPK and DAPK3 from the CAMK family with IC50 of 50 nM and 81 nM, respectively. GSK690693 affects Unc-51-like autophagy activating kinase 1 (ULK1) activity, robustly inhibits STING-dependent IRF3 activation. Phase 1.
Perifosine (KRX-0401)

Perifosine (KRX-0401, NSC639966, D21266) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Triciribine (NSC 154020)

Triciribine (NSC 154020, VD-0002, vqd-002, API-2, TCN) is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.
Honokiol (NSC 293100)

Honokiol (NSC 293100) is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Honokiol causes G0/G1 phase arrest, induces apoptosis, and autophagy via the ROS/ERK1/2 signaling pathway. Honokiol inhibits hepatitis C virus (HCV) infection. Phase 3.

Choose Your Country or Region

By Signaling Pathways

By product type

Afuresertib (GSK2110183)